Ove Törring

6.0k total citations · 1 hit paper
82 papers, 4.3k citations indexed

About

Ove Törring is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Molecular Biology. According to data from OpenAlex, Ove Törring has authored 82 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Oncology and 24 papers in Molecular Biology. Recurrent topics in Ove Törring's work include Bone health and treatments (24 papers), Thyroid Disorders and Treatments (23 papers) and Bone health and osteoporosis research (17 papers). Ove Törring is often cited by papers focused on Bone health and treatments (24 papers), Thyroid Disorders and Treatments (23 papers) and Bone health and osteoporosis research (17 papers). Ove Törring collaborates with scholars based in Sweden, Denmark and United States. Ove Törring's co-authors include Göran Wallin, G. E. F. Lundell, Leif Tallstedt, Mirna Abraham‐Nordling, Adam Taube, J.‐G. Ljunggren, Michael R. McClung, Steven R. Cummings, Christian Roux and Jan Calissendorff and has published in prestigious journals such as New England Journal of Medicine, The Journal of Clinical Endocrinology & Metabolism and Endocrinology.

In The Last Decade

Ove Törring

80 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

2017 458 citations Serge Ferrari, Nigel Gilchrist et al. Journal of Bone and Mineral Research profile →

Peers

Countries citing papers authored by Ove Törring

Since Specialization

Citations

This map shows the geographic impact of Ove Törring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ove Törring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ove Törring more than expected).

Fields of papers citing papers by Ove Törring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ove Törring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ove Törring. The network helps show where Ove Törring may publish in the future.

Co-authorship network of co-authors of Ove Törring

This figure shows the co-authorship network connecting the top 25 collaborators of Ove Törring. A scholar is included among the top collaborators of Ove Törring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ove Törring. Ove Törring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Long-Term Outcome of Treatment for Graves' Hyperthyroidism 2019 ·Thyroid ·Gabriel Sjölin, Mats Holmberg, Ove Törring, (unknown), (unknown), (unknown), Mirna Abraham‐Nordling, Jan Calissendorff, Mikael Lantz, Bengt Hallengren, Helena Filipsson Nyström, Göran Wallin	64
2	Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey 2019 ·Thyroid ·Ove Törring, Torquil Watt, Gabriel Sjölin, (unknown), Mirna Abraham‐Nordling, Jan Calissendorff, Per Karkov Cramon, Helena Filipsson Nyström, Bengt Hallengren, Mats Holmberg, (unknown), Mikael Lantz, Göran Wallin	64
3	Three Sisters With Heterozygous Gene Variants of CYP24A1: Maternal Hypercalcemia, New-Onset Hypertension, and Neonatal Hypoglycemia 2018 ·Journal of the Endocrine Society ·(unknown), Christina Pilo, (unknown), Ove Törring, Jan Calissendorff	11
4	Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter 2017 ·Thyroid ·(unknown), Mårten Rosenqvist, Viveka Frykman, Leif Friberg, Göran Wallin, Jonas Höijer, Stefan Lönn, Ove Törring	17
5	Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension 2014 ·Open Repository and Bibliography (University of Liège) ·Serge Ferrari, (unknown), Kurt Lippuner, Carol Zapalowski, P. D. Miller, Jean‐Yves Reginster, Ove Törring, (unknown), (unknown), (unknown), C. D. O’Malley, Cesar Libanati, (unknown), E. Michael Lewiecki	4
6	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis 2012 ·Menopause The Journal of The North American Menopause Society ·James A. Simon, Christopher Recknor, Alfred H. Moffett, Jonathan D. Adachi, Edward Franek, E. Michael Lewiecki, Michael R. McClung, C. Mautalén, Sergio Ragi-Eis, Geoffrey C. Nicholson, Christian Muschitz, Ranuccio Nuti, Ove Törring, Andrea Wang, Cesar Libanati	32
7	Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial 2012 ·Journal of Bone and Mineral Research ·Jacques P. Brown, Christian Roux, Ove Törring, Pei‐Ran Ho, Jens‐Erik Beck Jensen, Nigel Gilchrist, Christopher Recknor, Matt Austin, Andrea Wang, Andreas Grauer, Rachel B. Wagman	108
8	Emerging Anabolic Treatments in Osteoporosis 2011 ·Current Drug Safety ·Leif Mosekilde, Ove Törring, Lars Rejnmark	35
9	Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine 2010 ·European Journal of Endocrinology ·Mirna Abraham‐Nordling, Göran Wallin, Frank Träisk, Gertrud E. B. Berg, Jan Calissendorff, Bengt Hallengren, Pavo Hedner, Mikael Lantz, Ernst Nyström, Peter Åsman, G. E. F. Lundell, Ove Törring, (unknown)	26
10	Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131 2009 ·The Journal of Clinical Endocrinology & Metabolism ·Frank Träisk, Leif Tallstedt, Mirna Abraham‐Nordling, Tommy Andersson, Gertrud E. B. Berg, Jan Calissendorff, Bengt Hallengren, Pavo Hedner, Mikael Lantz, Ernst Nyström, Vesna Ponjavic, Adam Taube, Ove Törring, Göran Wallin, Peter Åsman, G. E. F. Lundell, (unknown)	172
11	Hyperthyroidism and suicide: a retrospective cohort study in Sweden 2009 ·European Journal of Endocrinology ·Mirna Abraham‐Nordling, Stefan Lönn, Göran Wallin, Li Yin, Olof Nyrén, (unknown), Per Hall, Ove Törring	10
12	Weak Evidence of Thyrotropin Receptors in Primary Cultures of Human Osteoblast-like Cells 2004 ·Calcified Tissue International ·Jon A. Tsai, Annika Janson, E. Bucht, Henrik Kindmark, Claude Marcus, André Stark, Helen Zemack, Ove Törring	45
13	Calcium and vitamin D3 supplements in calcium and vitamin D3 sufficient early postmenopausal healthy women 2004 ·European Journal of Clinical Nutrition ·Jacob Tfelt‐Hansen, Ove Törring	2
14	Extracellular Calcium Increases Free Cytoplasmic Calcium and DNA Synthesis in Human Osteoblasts 2004 ·Hormone and Metabolic Research ·Jon A. Tsai, E. Bucht, Ove Törring, Henrik Kindmark	5
15	Interleukin-1β Upregulates PTHrP-mRNA Expression and Protein Production and Decreases TGF-β in Normal Human Osteoblast-Like Cells 2000 ·Calcified Tissue International ·Jon A. Tsai, Haiqin Rong, Ove Törring, Hiroshi Matsushita, E. Bucht	18
16	Quality of Life Aspects and Costs in Treatment of Graves' Hyperthyroidism with Antithyroid Drugs, Surgery, or Radioiodine: Results from a Prospective, Randomized Study 1998 ·Thyroid ·Jan‐Gustaf Ljunggren, Ove Törring, Göran Wallin, Adam Taube, Leif Tallstedt, Bertil Hamberger, G. E. F. Lundell	70
17	Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism 1991 ·Bone ·Ove Törring, E. Bucht, (unknown), H. E. Sjöberg	11
18	The Anabolic Effects of Human Parathyroid Hormone (hPTH) on Rat Vertebral Body Mass Are also Reflected in the Quality of Bone, Assessed by Biomechanical Testing: A Comparison Study between hPTH-(1–34) and hPTH-(1–84)* 1991 ·Endocrinology ·Li. Mosekilde, C.H. Søgaard, Carl Christian Danielsen, Ove Törring, Magnus Nilsson	148
19	Experimental and immunohistochemical studies on the possible role of parathyroid hormone in uraemic pruritus 1989 ·Journal of Internal Medicine ·Mona Ståhle‐Bäckdahl, Ö Hägermark, L.-E. Lins, Ove Törring, Marita Hilliges, O. Johansson	42
20	Disodium etidronate in hypercalcaemia due to immobilisation. 1984 ·BMJ ·E Hägg, Malin Eklund, Ove Törring	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact